Abstract:Purpose: Glial fibrillary acidic protein serves as a biomarker indicative of astroglial injury, particularly following instances of severe traumatic brain injury. This study aims to evaluate variations in serum glial fibrillary acidic protein levels within the first 3 days and their correlation with outcomes in patients with severe traumatic brain injury. Subjects and methods: Thirty-nine patients with severe traumatic brain injury were enrolled in the study. Their blood samples were collected at six distinct time points: T0 (upon admission), T1, T2, T3, T4, and T5 (6-, 12-, 24-, 48-, and 72-h post-admission, respectively). The blood samples were run for the quantification of serum glial fibrillary acidic protein levels and other biochemical tests. All patients were closely watched and the outcomes at discharge were evaluated. Results: Glial fibrillary acidic protein levels tend to increase gradually from the time of admission to 48 h post-admission and then decrease at 72 h post-admission. Glial fibrillary acidic protein T2 is correlated with Acute Physiology and Chronic Health Evaluation II score, lactate, Simplified Acute Physiology Score II score and outcome. Glial fibrillary acidic protein max correlated with lactate, Acute Physiology and Chronic Health Evaluation II score, Simplified Acute Physiology Score II score, and outcome. Glasgow Coma Score at admission and glial fibrillary acidic protein T2 (OR = 1.034; p = 0.025), T3 (OR = 1.029; p = 0.046), T4 (OR = 1.006; p = 0.032), T5 (OR = 1.012; p = 0.048) and glial fibrillary acidic protein max (OR = 1.005; p = 0.010) were independent factors that have significant prognostic value in mortality in patients with severe traumatic brain injury. The predictive model in predicting mortality had the highest area under the curve based on glial fibrillary acidic protein T2 and Glasgow Coma Score T0 with an area under the curve of 0.904 and p < 0.001. In the multivariable regression model, glial fibrillary acidic protein max was associated with Glasgow score (p < 0.001; VIF = 1.585), lactate T0 (p = 0.024; VIF = 1.163), Acute Physiology and Chronic Health Evaluation II score (p = 0.037; VIF = 1.360), and Rotterdam score (p = 0.044; VIF = 1.713). Conclusion: Glial fibrillary acidic protein levels tend to increase gradually from the time of admission to 48 h post-admission then decreases at 72 h post-admission. Glial fibrillary acidic protein T2, T3, T4, T5, and glial fibrillary acidic protein max were independent factors with significant prognostic mortality values in patients with severe traumatic brain injury.

Central GLP-1 Resistance Induced by Severe Traumatic Brain Injury Was Associated with Persistent Hyperglycemia in Humans.

Peripheral Inflammatory Markers in Patients with Prolonged Disorder of Consciousness after Severe Traumatic Brain Injury.

Change in Plasma Microparticle Procoagulant Activity after Traumatic Brain Injury

Time course of plasma leptin concentrations after acute spontaneous basal ganglia hemorrhage.

Effects of Glucose Monitoring after Traumatic Brain Injury on Predicting Prognosis of the Patients

Prognostic Significance of Plasma Insulin Level for Deep Venous Thrombosis in Patients with Severe Traumatic Brain Injury in Critical Care.

Effect of blood glucose fluctuation on the prognosis of severe traumatic brain injury patients

Insulin resistance is associated with an unfavorable outcome among non-diabetic patients with isolated moderate-to-severe traumatic brain injury – A propensity score-matched study

Analysis on Blood Glucose,Creatinine Changes and Outcomes of Craniocerebral Trauma

Changes in the levels of serum glial fibrillary acidic protein and the correlation with outcomes in severe traumatic brain injury patients

Influence of glibenclamide on outcome in patients with type 2 diabetes and traumatic brain injury.

Glial Fibrillary Acidic Protein As a Biomarker in Severe Traumatic Brain Injury Patients: a Prospective Cohort Study

Dependability analysis of hyperglycosemia and prognosis of patients with severe craniocerebral trauma

Chronic Neurobehavioral Impairments and Decreased Hippocampal Expression of Genes Important for Brain Glucose Utilization in a Mouse Model of Mild TBI

Inpatient rehabilitation, blood glucose, and the outcome of TBI

Diagnostic and prognostic utility of plasma thrombospondin-1 levels in traumatic brain injury

Effect of early intensive insulin therapy on high mobility group box 1 protein levels and prognosis of patients with severe trauma

Plasma Glucagon-Like Peptide 1 Was Associated with Hospital-Acquired Infections and Long-Term Mortality in Burn Patients.

Continuous Measurement of the Cumulative Amplitude and Duration of Hyperglycemia Best Predicts Outcome after Traumatic Brain Injury

Impact of Intensive Insulin Therapy on Clinical Outcomes of Traumatic Brain Injury Patients with Pre-Existing Diabetes

Clinical Predictors of Prognosis in Patients with Traumatic Brain Injury Combined with Extracranial Trauma